SCHEMBL336288

SCHEMBL336288

CC(C)OC(=O)/C=C/c1ccco1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 11/20 0.59
CACNA1B Q00975 1/20 0.59
APBA1 Q02410 1/20 0.59
HCAR2 Q8TDS4 1/20 0.57
TDP1 Q9NUW8 3/20 0.56
ALDH1A1 P00352 6/20 0.56
L3MBTL1 Q9Y468 4/20 0.56
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
MAPT P10636 3/20 0.52
PKM P14618 2/20 0.52
NPSR1 Q6W5P4 1/20 0.52
HPGD P15428 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
CA12 O43570 1/20 0.51
AKR1B10 O60218 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
AKR1B1 P15121 1/20 0.51
CA7 P43166 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23175323 1.00 POLB (0.59) POLBCACNA1BAPBA1HCAR2TDP1
SCHEMBL7138125 0.92 POLB (0.60) POLBCACNA1BAPBA1HCAR2TDP1
SCHEMBL7138121 0.92 POLB (0.60) POLBCACNA1BAPBA1HCAR2TDP1
SCHEMBL7588375 0.83 POLB (0.62) POLBCACNA1BAPBA1HCAR2TDP1
SCHEMBL7588372 0.83 POLB (0.62) POLBCACNA1BAPBA1HCAR2TDP1
SCHEMBL1286936 0.81 POLB (0.67) POLBCACNA1BAPBA1HCAR2TDP1
SCHEMBL1286940 0.81 POLB (0.67) POLBCACNA1BAPBA1HCAR2TDP1
SCHEMBL7141083 0.81 HCAR2 (0.67) POLBCACNA1BAPBA1HCAR2TDP1
SCHEMBL7141082 0.81 HCAR2 (0.67) POLBCACNA1BAPBA1HCAR2TDP1
SCHEMBL11278963 0.81 POLB (0.50) POLBCACNA1BAPBA1HCAR2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP disclosed
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP disclosed
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US disclosed
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US disclosed
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US disclosed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US disclosed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US disclosed
EP-2069289-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS Sanofi-Aventis (FR) 2009-06-17 EP disclosed
WO-2008031509-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI-AVENTIS (FR) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 POLB 3780/4885CACNA1B 1395/4885APBA1 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.